CYBN
Price
$5.94
Change
-$0.52 (-8.05%)
Updated
Nov 13 closing price
Capitalization
322.55M
Intraday BUY SELL Signals
EYPT
Price
$11.51
Change
-$0.48 (-4.00%)
Updated
Nov 13 closing price
Capitalization
952.88M
111 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CYBN vs EYPT

Header iconCYBN vs EYPT Comparison
Open Charts CYBN vs EYPTBanner chart's image
Cybin
Price$5.94
Change-$0.52 (-8.05%)
Volume$1.14M
Capitalization322.55M
EyePoint Pharmaceuticals
Price$11.51
Change-$0.48 (-4.00%)
Volume$1.14M
Capitalization952.88M
CYBN vs EYPT Comparison Chart in %
CYBN
Daily Signal:
Gain/Loss:
EYPT
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CYBN vs. EYPT commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYBN is a Hold and EYPT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (CYBN: $5.94 vs. EYPT: $11.51)
Brand notoriety: CYBN and EYPT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYBN: 131% vs. EYPT: 86%
Market capitalization -- CYBN: $322.55M vs. EYPT: $952.88M
CYBN [@Biotechnology] is valued at $322.55M. EYPT’s [@Biotechnology] market capitalization is $952.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYBN’s FA Score shows that 1 FA rating(s) are green whileEYPT’s FA Score has 1 green FA rating(s).

  • CYBN’s FA Score: 1 green, 4 red.
  • EYPT’s FA Score: 1 green, 4 red.
According to our system of comparison, EYPT is a better buy in the long-term than CYBN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYBN’s TA Score shows that 3 TA indicator(s) are bullish while EYPT’s TA Score has 1 bullish TA indicator(s).

  • CYBN’s TA Score: 3 bullish, 6 bearish.
  • EYPT’s TA Score: 1 bullish, 8 bearish.
According to our system of comparison, CYBN is a better buy in the short-term than EYPT.

Price Growth

CYBN (@Biotechnology) experienced а -2.14% price change this week, while EYPT (@Biotechnology) price change was +3.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.47%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +62.00%.

Reported Earning Dates

EYPT is expected to report earnings on Mar 05, 2026.

Industries' Descriptions

@Biotechnology (+1.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EYPT($953M) has a higher market cap than CYBN($323M). EYPT YTD gains are higher at: 54.497 vs. CYBN (-32.653). CYBN has higher annual earnings (EBITDA): -152.51M vs. EYPT (-172.05M). EYPT has more cash in the bank: 256M vs. CYBN (119M). EYPT has less debt than CYBN: EYPT (21.8M) vs CYBN (44.5M). EYPT has higher revenues than CYBN: EYPT (51.9M) vs CYBN (0).
CYBNEYPTCYBN / EYPT
Capitalization323M953M34%
EBITDA-152.51M-172.05M89%
Gain YTD-32.65354.497-60%
P/E RatioN/AN/A-
Revenue051.9M-
Total Cash119M256M46%
Total Debt44.5M21.8M204%
FUNDAMENTALS RATINGS
CYBN vs EYPT: Fundamental Ratings
CYBN
EYPT
OUTLOOK RATING
1..100
797
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
69
Overvalued
PROFIT vs RISK RATING
1..100
9779
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
6143
P/E GROWTH RATING
1..100
10013
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYBN's Valuation (20) in the null industry is somewhat better than the same rating for EYPT (69) in the Pharmaceuticals Major industry. This means that CYBN’s stock grew somewhat faster than EYPT’s over the last 12 months.

EYPT's Profit vs Risk Rating (79) in the Pharmaceuticals Major industry is in the same range as CYBN (97) in the null industry. This means that EYPT’s stock grew similarly to CYBN’s over the last 12 months.

CYBN's SMR Rating (97) in the null industry is in the same range as EYPT (98) in the Pharmaceuticals Major industry. This means that CYBN’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's Price Growth Rating (43) in the Pharmaceuticals Major industry is in the same range as CYBN (61) in the null industry. This means that EYPT’s stock grew similarly to CYBN’s over the last 12 months.

EYPT's P/E Growth Rating (13) in the Pharmaceuticals Major industry is significantly better than the same rating for CYBN (100) in the null industry. This means that EYPT’s stock grew significantly faster than CYBN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYBNEYPT
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 18 days ago
78%
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 10 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CYBN
Daily Signal:
Gain/Loss:
EYPT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAIGF10.900.15
+1.40%
AIA Group, Ltd.
AHFCF0.57N/A
N/A
Flow Cap Corp.
RHCGF1.75N/A
N/A
Ryman Healthcare Ltd.
VMTHF0.31N/A
N/A
VENUS MEDTECH HANGZHOU INC.
NIABY4.04-0.07
-1.70%
Nibe Industrier AB

CYBN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYBN has been loosely correlated with ATAI. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CYBN jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYBN
1D Price
Change %
CYBN100%
-8.05%
ATAI - CYBN
40%
Loosely correlated
-4.62%
ABSI - CYBN
35%
Loosely correlated
-22.35%
RXRX - CYBN
35%
Loosely correlated
-6.88%
ABCL - CYBN
33%
Poorly correlated
-8.82%
EYPT - CYBN
33%
Poorly correlated
-4.00%
More

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with LYRA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then LYRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
-4.00%
LYRA - EYPT
58%
Loosely correlated
-1.55%
OCUL - EYPT
55%
Loosely correlated
-2.61%
ATHE - EYPT
54%
Loosely correlated
-2.64%
ERAS - EYPT
52%
Loosely correlated
-4.15%
CGON - EYPT
48%
Loosely correlated
-4.19%
More